In recent years, 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA) positron emissions tomography (PET)/computed tomography (CT) has become firmly established in the clinical routine of prostate cancer diagnostics. This evidence concerns the gene FOLH1 and prostate cancer.